Novartis Submits Application in China for Groundbreaking Autoimmune Drug
Stock News
Feb 06
On February 6th, regulatory filings revealed that Novartis AG has submitted an application in China for the approval of ianalumab. Ianalumab is a fully human monoclonal antibody targeting the BAFF-R receptor, which Novartis obtained through its acquisition of MorphoSys. The drug features a dual mechanism of action, depleting B cells while also inhibiting the BAFF-R pathway. It is intended for the treatment of various autoimmune conditions, including Sjögren's syndrome, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). This medication is the first anti-BAFF-R antibody to have completed Phase III clinical studies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.